Home » Stocks » LivaNova

LivaNova PLC (LIVN)

Stock Price: $46.73 USD -0.65 (-1.37%)
Updated Aug 6, 2020 11:41 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.27B
Revenue (ttm) 980.80M
Net Income (ttm) -161.52M
Shares Out 48.67M
EPS (ttm) -3.33
PE Ratio n/a
Forward PE 46.73
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $46.73
Previous Close $47.38
Change ($) -0.65
Change (%) -1.37%
Day's Open 47.14
Day's Range 46.62 - 47.99
Day's Volume 61,036
52-Week Range 33.40 - 87.45

More Stats

Market Cap 2.27B
Enterprise Value 2.73B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 48.67M
Float 48.43M
EPS (basic) -3.33
EPS (diluted) -3.33
FCF / Share -4.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.16M
Short Ratio 4.38
Short % of Float 6.80%
Beta 0.84
PE Ratio n/a
Forward PE 46.73
P/FCF Ratio n/a
PS Ratio 2.32
PB Ratio 1.81
Revenue 980.80M
Operating Income -132.84M
Net Income -161.52M
Free Cash Flow -230.64M
Net Cash -456.48M
Net Cash / Share -9.38
Gross Margin 74.59%
Operating Margin -13.54%
Profit Margin -16.50%
FCF Margin -23.51%
ROA -1.08%
ROE -11.41%
ROIC -15.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$65.00*
(39.10% upside)
Low
52.0
Current: $46.73
High
86.0
Target: 65.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue1,0841,1071,012965292282254681
Revenue Growth-2.06%9.35%4.91%230.93%3.38%10.89%-62.63%-
Gross Profit745734652559264255232371
Operating Income-169-23712733.4588.6580.0178.3533.22
Net Income-155-189-25.09-62.7957.8554.8946.3618.24
Shares Outstanding48.3548.5048.1648.8626.3927.1427.60-
Earnings Per Share-3.21-3.91-0.52-1.282.172.001.660.04
EPS Growth----8.5%20.48%4511.11%-
Operating Cash Flow-91.1412091.3490.1579.6854.2079.0571.59
Capital Expenditures-24.69-37.19-32.93-38.36-6.69-15.22-9.71-19.97
Free Cash Flow-11683.3058.4151.7972.9938.9769.3551.61
Cash & Equivalents61.1447.2093.6239.791511280.000.00
Total Debt384168146123----
Net Cash / Debt-323-121-52.38-83.081511280.000.00
Assets2,4122,5502,5042,343316294--
Liabilities1,0281,04668963639.3735.09--
Book Value1,3841,5041,8151,707277259--
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name LivaNova PLC
Country United Kingdom
Employees 4,000
CEO Damien McDonald

Stock Information

Ticker Symbol LIVN
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: LIVN
IPO Date February 10, 1993

Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.